A non-occlusive thrombus is a blood clot that only partially blocks a blood vessel, leaving some room for blood to continue flowing past it. This distinguishes it from an occlusive thrombus, which completely seals off the vessel. The difference matters because partial blockage often produces milder or even no symptoms, but the clot can still grow, break loose, or cause serious complications depending on where it forms.
How a Non-Occlusive Clot Forms
Blood clots develop when the normal balance between clotting and flow breaks down. In healthy vessels, blood moves smoothly and clotting factors stay inactive. Problems start when a vessel wall is damaged, blood flow slows or becomes turbulent, or the blood itself becomes more prone to clotting. These three factors, first described in the 1800s, still explain most clot formation today.
In narrowed arteries, the mechanics get more specific. Where plaque buildup squeezes a vessel, blood accelerates through the tight spot and creates extreme shear forces. These forces physically stretch certain proteins in the blood (particularly one called von Willebrand factor), which unfolds and exposes sticky binding sites that grab passing platelets. Platelets pile up at the narrowing, and clot-promoting chemicals amplify the process. Just past the narrowed section, blood swirls in a slow recirculation zone where clotting material accumulates further. The result is often a clot that narrows the vessel significantly but doesn’t seal it shut.
In veins, the process is different. Slow-moving blood in the deep veins of the legs, especially after surgery, immobility, or illness, allows clotting factors to concentrate and trigger a clot. These clots frequently start small and non-occlusive before they either dissolve on their own or grow large enough to block the vessel entirely.
Where Non-Occlusive Clots Typically Appear
The most common locations are the deep veins of the legs, the coronary arteries that feed the heart, and occasionally large central vessels like the inferior vena cava. Postoperative patients are particularly likely to develop small, non-occlusive clots in the veins below the knee, often without any symptoms at all.
In the coronary arteries, a non-occlusive clot typically forms over a ruptured plaque. This is the mechanism behind unstable angina and certain types of heart attack. The clot reduces blood flow enough to starve the heart muscle of oxygen but doesn’t cut it off completely, which is why the damage tends to be less severe than in a full blockage.
Non-Occlusive Clots and Heart Events
The relationship between partial coronary clots and heart attacks is one of the most clinically important aspects of this topic. Acute coronary syndromes, the umbrella term for unstable angina and heart attacks, are nearly all caused by plaque rupture followed by clot formation. What determines the severity is how completely the clot blocks the artery and how long the blockage lasts.
Research published in Circulation outlines a rough timeline: if a coronary artery is totally blocked for less than about 20 minutes before flow resumes, the result is typically unstable angina with no permanent heart damage. Blockage lasting 20 minutes to 2 hours tends to cause a smaller heart attack (non-Q-wave infarction). Beyond 2 hours, extensive damage occurs. In non-Q-wave heart attacks, angiography within 24 hours of symptom onset found the artery was still open in 74% of patients, compared to only 19% in the more severe Q-wave infarctions. The clots in milder events contain more platelets and less of the tough fibrin protein, making them less stable. They tend to form and partially dissolve repeatedly rather than locking into a solid blockage.
Symptoms of Partial Vessel Blockage
Symptoms vary enormously depending on location and how much the clot restricts flow. In the leg veins, the clinical picture ranges from completely silent to noticeable swelling and pain. About 70% of people with symptomatic deep vein clots experience swelling, and roughly 50% report pain. Other signs include redness, warmth, tenderness, prominent surface veins, and pain when flexing the foot upward. Small, non-occlusive clots in the calf veins frequently cause no symptoms whatsoever, which is why they’re often discovered incidentally during imaging for other reasons.
In the coronary arteries, a non-occlusive clot usually announces itself as chest pain or pressure that comes on at rest or with minimal exertion, sometimes radiating to the arm, jaw, or back. Because blood still flows past the clot, the pain may come and go as the clot shifts or the artery spasms around it.
How It’s Diagnosed
Ultrasound is the first-line tool for detecting clots in the leg veins. It can show whether a clot partially or fully fills the vessel and whether the vein still compresses normally under pressure. For clots in deeper or harder-to-reach vessels like the inferior vena cava, contrast-enhanced MRI is considered a reference standard, offering detailed 3D images of the vessel and clot. Catheter-based venography, where contrast dye is injected directly into the vein and X-rays are taken, remains the gold standard for the most precise assessment. Intravascular ultrasound, a tiny probe threaded inside the vessel, can measure the vessel diameter and clot location with even greater accuracy than venography.
Imaging doesn’t just confirm a clot exists. It also determines how much of the vessel is blocked, whether the clot is fresh or old, and whether it’s growing. These details directly shape treatment decisions.
Treatment and Duration
Blood-thinning medication is the cornerstone of treatment for non-occlusive clots. The goal is to prevent the clot from growing or breaking off while the body’s own clot-dissolving system works to clear it. Treatment duration depends on what triggered the clot in the first place.
If a clear, temporary cause exists, such as recent surgery, a long flight, or a leg injury, 3 months of anticoagulation is the standard recommendation. Some patients with provoked clots are treated for up to 6 months. When no obvious trigger can be identified (an “unprovoked” clot), the risk of recurrence is considerably higher, and guidelines favor indefinite anticoagulation as long as bleeding risk remains low and the patient is willing to continue. For people with active cancer, anticoagulation generally continues for as long as the cancer is being treated.
One evolving approach ties the duration of treatment to imaging results rather than a fixed calendar. In this strategy, patients continue anticoagulation until ultrasound confirms the vein has reopened, with checks at roughly 3, 9, 15, and 21 months. This “flexible dosing” model aims to avoid stopping treatment too early in patients whose clots are slow to resolve.
Risk of the Clot Breaking Loose
The most feared complication of a non-occlusive clot in a deep vein is pulmonary embolism, where a piece of the clot detaches and travels to the lungs. Silent pulmonary embolism, meaning it happens without obvious symptoms, develops in up to 40% to 50% of people with deep vein thrombosis. This is one reason even a small, partial clot is treated seriously.
Non-occlusive clots may actually carry a particular risk of embolization precisely because they sit in flowing blood. An occlusive clot, firmly wedged in place and sealed against the vessel wall, may be somewhat anchored. A partial clot jutting into moving blood faces constant mechanical stress that can shear off fragments.
Recurrence and Long-Term Outlook
Clots can come back. In a real-world study published in Nature’s Scientific Reports, about 21% of patients with recurrent venous clots who had stopped anticoagulation died within 90 days of the recurrence, a nearly identical mortality rate to those who had a recurrence while still on blood thinners. Patients on warfarin who experienced recurrence faced a 6.8% risk of yet another clot and a 2.3% risk of major bleeding within 3 months.
These numbers underscore why the initial decision about treatment duration is so consequential. The calculus is always a tension between the risk of another clot if you stop treatment and the risk of serious bleeding if you continue. For unprovoked clots, the recurrence rate is high enough that most specialists lean toward longer treatment. For provoked clots with a clear, resolved trigger, the recurrence risk drops substantially and shorter courses are appropriate.
Long-term, some people develop post-thrombotic syndrome in the affected leg, with chronic swelling, heaviness, or skin changes, even after the clot itself is gone. Compression stockings and staying active can help manage these symptoms. The degree of long-term damage generally correlates with how much of the vein was blocked and how quickly treatment began, which is why even a non-occlusive clot benefits from prompt diagnosis and care.